Abstract:Cytokines are known to shape the tumor microenvironment and although progress has been made in understanding their role in carcinogenesis, much remains to learn regarding their role in tumor growth and progression. We have identified granulocyte colony-stimulating factor (G-CSF) as one such cytokine, showing that G-CSF is linked with metastasis in human gastrointestinal tumors and neutralizing G-CSF in a mouse model of colitis-associated cancer is protective. Here, we set out to identify the role of G-CSF and its receptor, G-CSFR, in CD4+ and CD8+ T cell responses in the tumor microenvironment. MC38 colon cancer cells were injected into WT, G-CSFR−/− mice, or Rag2−/− mice. Flow cytometry, Real Time PCR and Multiplex cytokine array analysis were used for in vitro T cell phenotype analysis. Adoptive transfer of WT or G-CSFR−/− CD4+ of CD8+ T cells were performed. Mouse tumor size, cytokine expression, T cell phenotype, and cytotoxic activity were analyzed. We established that in G-CSFR−/− mice, tumor growth of MC38 colon cancer cells is significantly decreased. T cell phenotype and cytokine production were also altered, as both in vitro and in vivo approaches revealed that the G-CSF/G-CSFR stimulate IL-10-producing, FoxP3-expressing CD4+ and CD8+ T cells, whereas G-CSFR−/− T cells exhibit increased IFNγ and IL-17A production, leading to increased cytotoxic activity in the tumor microenvironment. Furthermore, peritumoral injection of recombinant IFNγ or IL-17A inhibited colon and pancreas tumor growth compared to controls. Taken together, our data reveal an unknown mechanism by which G-CSF, through its receptor G-CSFR, promotes an inhibitory Treg phenotype that limits tumor immune responses and furthermore suggest that targeting this cytokine/receptor axis could represent a novel therapeutic approach for gastrointestinal, and likely other tumors with high expression of these factors.

The Galaninergic System: A Target for Cancer Treatment

The role of galanin in the progression and prognosis of colorectal cancer: the unfinished story

Cmet As A Potential Therapeutic Target In Gastric Cancer

Agonists of galanin subtype 2 receptor may prevent pancreatic cancer and agonists of angiotensin II type 2 receptor may prevent colorectal cancer

Galanin Suppresses Proliferation of Human U251 and T98G Glioma Cells Via Its Subtype 1 Receptor.

Galanin, galanin receptors and drug targets

Peptidergic Systems and Cancer: Focus on Tachykinin and Calcitonin/Calcitonin Gene-Related Peptide Families

Galanin receptors as a potential target for neurological disease

Role and Regulation Mechanism of Gal-3 in Non-Small Cell Lung Cancer and Its Potential Clinical Therapeutic Significance.

Expression of galanin and its receptor subtypes in human breast cancer

Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk

Galectins in Cancer and the Microenvironment: Functional Roles, Therapeutic Developments, and Perspectives

CXCR4: From Signaling to Clinical Applications in Neuroendocrine Neoplasms

Theranostic Approaches for Gastric Cancer: An Overview of In Vitro and In Vivo Investigations

Gallic Acid: A Potential Anti-Cancer Agent

G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor Growth and Are Potential Therapeutic Targets

Gastrins, cholecystokinins and gastrointestinal cancer

The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies

NEUROENDOCRINE PEPTIDES IN THE PATHOGENESIS OF COLORECTAL CARCINOMA

The GAL/GALR2 axis promotes the perineural invasion of salivary adenoid cystic carcinoma via epithelial‐to‐mesenchymal transition

Galectin-1 Inhibition Induces Cell Apoptosis Through Dual Suppression of CXCR4 and Ras Pathways in Human Malignant Peripheral Nerve Sheath Tumors.